Document is current
Any future updates will be listed below
-
Authors
Yang, Yi
He, Xiao
Yao, Mengwei
Li, Zhan
Xing, Wei
Zheng, Song Guo
Xu, Xiang https://orcid.org/0000-0002-1026-2210
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82372529)
National Natural Science Foundation of China (32100643)
Science Foundation of State Key laboratory of Trauma and Chemical Poisoning (2024K003)
Major scientific and Technological Projects of Yunnan Province (202502AA310012)
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 20 October 2025
First Online: 17 November 2025
Declarations
:
: This study was approved by the Ethics Committee of Daping Hospital, Army Military Medical University of the Chinese People’s Liberation Army (Approval ID: YIYANLUNSHEN (2016) NO. 007) on March 6, 2016, under the title “Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA)” and (Approval ID: YIYANLUNSHEN (2016) NO.016) on September 25, 2016, under the title “Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells combined with recombinant human gamma interferon (IFN-γ) in the treatment of Rheumatoid Arthritis (RA)”.
: All enrolled patients have provided written informed consent for participation in the study and the use of samples.
: The authors declare that there is no conflict of interest.
